FEMY (Femasys) Moat Score: 3/10 (As of Jul. 01, 2026)


FEMY Femasys Inc FEMY
55 GF Score
Price $4.35
GF Value $12.19
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Femasys Moat Score?

Femasys FEMY +4.44% 55 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.19 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Femasys ranks better than 75.89% on this metric.

Femasys has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Femasys has No Moat: Femasys operates in a competitive medical device industry with limited market share and lacks significant intellectual property or regulatory barriers. The company has potential for innovation but currently does not possess strong customer loyalty or pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Femasys might have No Moat - Very weak/transient advantages.

Femasys  (NAS:FEMY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Femasys Moat Score Related Terms

FEMY vs UEEC, BNGO, CUPR: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Femasys's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Femasys Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Moat Score distribution charts can be found below:

* The bar in red indicates where Femasys's Moat Score falls into.


FEMY
55GF Score
Femasys Inc FEMY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Femasys (FEMY) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Femasys ranks #204 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Femasys' Moat Score too high?
Femasys' current Moat Score is 3. Based on the distribution chart, Femasys ranks #204 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Moat Score compare to UEEC and BNGO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #204 out of 846 companies for Moat Score. This places Femasys in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Femasys's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.19, compared to a current price of $4.35 — trading 64.3% below its estimated fair value. The current Moat Score is 3. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Femasys (FEMY), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Femasys (FEMY) Overvalued in 2026?

Based on GuruFocus' analysis, Femasys stock appears to be undervalued. The current stock price of $4.35 is trading 64.3% below its estimated GF Value™ of $12.19. GuruFocus considers Femasys to be Possible Value Trap.

Key valuation signals for FEMY:

  • Moat Score: 3
  • GF Value™: $12.19 vs. price of $4.35 (64.3% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Femasys Business Description

Address 3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score

Get the complete analysis for FEMY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.35
Price
$12.19
GF Value